摘要
目的:评价芩香清解口服液用于儿童上呼吸道感染的经济性。方法:基于一项随机、双盲对照的临床研究,计算2组方案的成本和健康产出,进行短期成本-效果分析。采用条件价值评估法开展问卷调查,收集患者的意愿支付阈值。对关键指标进行单因素敏感性分析。结果:芩香清解口服液联用利巴韦林注射液组相对利巴韦林组增量成本效果比为8.34元,小于支付意愿阈值15.0元,芩香清解口服液联用利巴韦林注射液具有经济性。结论:芩香清解口服液联合利巴韦林注射液用于儿童上呼吸道感染是疗效佳、经济、安全的治疗方案,值得临床推荐。
Objective: To evaluate the economy of Qinxiang Qingjie oral liquid in treating children with upper respiratory tract infection. Method: Based on a randomized, double-blind, and controlled clinical study, the cost and health output of schemes in two groups were calculated, and a short-term cost-ef fectiveness analysis was carried out. The conditional value assessment method was used, and a questionnaire survey was carried out to collect the willing payment threshold of patients. A single factor sensitivity analysis was carried out for key indicators. Result: The ICER of Qinxiang Qingjie oral liquid combined with ribavirin injection group was 8.34 yuan compared with ribavirin group, which was less than the WTP threshold of 15.0 yuan. Qinxiang Qingjie oral liquid combined with ribavirin injection was more economical. Conclusion: Qinxiang Qingjie oral liquid combined with ribavirin injection is an ef fective, economical, and safe treatment for children with upper respiratory tract infection, which is worthy of clinical recommendation.
作者
胡海瑶
韩成龙
何慧琳
苟亮文
胡明
Hu Haiyao;Han Chenglong;He Huilin;Gou Liangwen;Hu Ming(West China School of Medicine,Sichuan University,Sichuan 610041,China;West China School of Pharmacy,Sichuan University,Sichuan 610041,China)
出处
《中国药事》
CAS
2022年第8期843-851,共9页
Chinese Pharmaceutical Affairs
关键词
成本-效果分析
芩香清解口服液
上呼吸道感染
意愿支付
cost-ef fectiveness analysis
Qinxiang Qingjie oral liquid
upper respiratory tract infection
willing ness to pay
